News

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Nant Capital’s investment of up to $22.3 million in a PIPE into PDS Biotech, along with Patrick Soon Shiong’s new board seat there, pushed ImmunityBio (NasdaqGS:IBRX) up 6% on Monday and sharpened focus on his broader immunotherapy plans. ImmunityBio’s share price has cooled slightly in the very short term, with a 1-day share price return of 2.75% and a 7-day share price return of 1.81%. However, the 30-day and 90-day share price returns of 7.53% and 16.45% suggest momentum is still building...

J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform.

ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.

A new patent application covers using Anktiva to restore immune cells depleted by cancer treatments.

Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.

ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.

Patrick Soon-Shiong said the trial has been fully accrued and passed its one-year mark.

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.

Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.

Vanguard held SLS and IBRX positions worth a combined $259 million at quarter-end.

ImmunityBio stock has delivered a very strong 321.9% return over the past three years, yet current valuation checks and recent price weakness raise questions about how much of the recent progress is already reflected in the share price. Over the last three years, ImmunityBio has returned 321.9%, which puts recent short term pullbacks into the context of a very strong multi year run. Approval for ANKTIVA in the UAE and growing commercial traction can support higher revenue expectations, while...

In the past week, ImmunityBio, Inc. received marketing authorization in the United Arab Emirates for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, while reporting second-quarter 2026 revenue of US$51.24 million and a net loss of US$230.38 million. The UAE decision gives ANKTIVA its broadest approval yet across the full spectrum of BCG-unresponsive bladder cancer and checkpoint-refractory lung cancer, extending ImmunityBio’s...

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

ImmunityBio’s record quarterly revenue of $51.2 million beat Wall Street’s estimates of $49.7 million, driven by the increased sales of Anktiva.

ImmunityBio (NASDAQ:IBRX) shares climbed 7. 5% on Thursday after the company announced that the United Arab Emirates had granted marketing approval for ANKTIVA in two cancer indications, further expanding the therapy’s international regulatory reach.

Weekend chatter focused on ImmunityBio’s quiet July, with some bulls calling the silence the “quiet before the kraken.”

ImmunityBio (IBRX) is back in focus after its stock surged 282.7% year to date, as investors weigh speculation around Anktiva’s role in bladder cancer treatment alongside ongoing regulatory and valuation questions. See our latest analysis for ImmunityBio. Recent trading shows that momentum in ImmunityBio’s share price has cooled in the near term, with a 7 day share price return down 12.16%, following a year to date share price return of 282.67% and a 1 year total shareholder return of...

Traders remain focused on Anktiva’s potential label expansion for papillary bladder cancer, with an FDA decision date set for Jan. 6, 2027.

Saudi Arabia is key to the bull case after ImmunityBio launched Anktiva there for certain patients with bladder and lung cancer.

ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.

ImmunityBio, Inc. (NASDAQ:IBRX) was among the stocks on which Jim Cramer commented, as he emphasized that SpaceX investors are betting on Elon Musk rather than the company’s earnings. When a caller mentioned that, as per their observation, the company seems to have become a “mid-cap commercial revenue generator” from a “small-cap spec play,” Cramer remarked: […]

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 10 Best Performing Growth Stocks So Far in 2026. On June 1, ImmunityBio, Inc. (NASDAQ:IBRX) reported that it presented two research posters and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held from May 29 to June 2, 2026, in Chicago. […]

Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.

ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The update included the first substantial ANKTIVA data readout in non small cell lung cancer and new comparative data in non muscle invasive bladder cancer. These ASCO presentations expand the clinical picture for ANKTIVA across major solid tumor types beyond bladder cancer. For investors following...